Press release content from Globe Newswire. The AP news staff was not involved in its creation.
European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple .
SanofiApril 19, 2021 GMT European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma
Approval based on Phase 3 IKEMA study demonstrating Sarclisa added to standard of care carfilzomib and dexamethasone reduced risk of disease progression or death by 47% in patients who had relapsed after one to three prior therapies
Sarclisa combination therapy was associated with undetectable levels of multiple myeloma (MM) in nearly 30% of patients with relapsed MM
Second EU approval in less than 12 months for Sarclisa in combination with a standard of care regimen for the treatment of relapsed or refractory MM
Press release content from Accesswire. The AP news staff was not involved in its creation.
CureVac Swiss AG Initiates Rolling Submission Process for mRNA-based COVID-19 Vaccine Candidate, CVnCoV, with Swissmedic
April 19, 2021 GMT
Review process started with submission of first CVnCoV data package
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 19, 2021 / The CureVac Swiss AG, the Swiss subsidiary of CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced initiation of a rolling submission for CVnCoV, the company’s mRNA based COVID-19 vaccine candidate, for the use in Switzerland. The application for authorization was submitted to Swissmedic, the country’s authority responsible for the authorization and supervision of therapeutic products including vaccines.
Press release content from Accesswire. The AP news staff was not involved in its creation.
Abivax Hosting Key Opinion Leader Webinar on ABX464 for the Treatment of Ulcerative Colitis
April 19, 2021 GMT
The Webinar takes place on Tuesday, April 20, 2021 at 7:30am EDT (1:30pm CEST)PARIS, FRANCE / ACCESSWIRE / April 19, 2021 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that .
The Webinar takes place on Tuesday, April 20, 2021 at 7:30am EDT (1:30pm CEST)PARIS, FRANCE / ACCESSWIRE / April 19, 2021 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that .
The Webinar takes place on Tuesday, April 20, 2021 at 7:30am EDT (1:30pm CEST)
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
CERiS Offers First Prepayment Dual Reviews For Payment Integrity Programs
CorVel Corp.April 19, 2021 GMT
FORT WORTH, Texas, April 19, 2021 (GLOBE NEWSWIRE) CERiS, a division of CorVel Healthcare and a leading national provider of cost containment solutions, now offers a comprehensive prospective claim review services for client firms that pay medical claims. The expanded service produces the most complete and accurate review available for both itemized bills and DRG (diagnostic-related groupings) validation.
“Our itemization review already has the industry’s best track record for correcting billed charges,” noted Corey Albrecht, President of CERiS. “For claims that pay a DRG base rate or an outlier payment and/or have carve-out language, we’re the first firm to deliver a complete package by offering full DRG validation review,” Albrecht remarked.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Ledyard Financial Group Reports Record Earnings
April 19, 2021 GMT
HANOVER, N.H. (BUSINESS WIRE) Apr 19, 2021
Ledyard Financial Group, Inc. (ticker symbol LFGP), the holding company for Ledyard National Bank, is proud to announce record earnings for the first quarter of 2021. Our focus continues to be strengthening our financial position, maintaining our strong liquidity position, and preserving core earnings. Our results demonstrate that our financial condition remains strong and that our core businesses continue to thrive in this prolonged difficult environment. As a community bank we continue to focus on our customers and their financial needs during these highly unusual times. We entered this crisis in a position of strength and remain focused on what we need to do to ensure we are able to support our core constituents. Net income for the quarter ended March 31, 2021, was $1,835,872